Although exertional dyspnea and worsening hypoxia are hallmark clinical features of idiopathic pulmonary fibrosis (IPF), no drug currently available could treat them. GBT1118 is a novel orally bioavailable small molecule that binds to hemoglobin and produces a concentration‐dependent left shift of the oxygen–hemoglobin dissociation curve with subsequent increase in hemoglobin–oxygen affinity and arterial oxygen loading. To assess whether pharmacological modification of hemoglobin–oxygen affinity could ameliorate hypoxemia associated with lung fibrosis, we evaluated GBT1118 in a bleomycin‐induced mouse model of hypoxemia and fibrosis. After pulmonary fibrosis and hypoxemia were induced, GBT1118 was administered for eight consecutive days. Hypoxemia was determined by monitoring arterial oxygen saturation, while the severity of pulmonary fibrosis was assessed by histopathological evaluation and determination of collagen and leukocyte levels in bronchoalveolar lavage fluid. We found that hemoglobin modification by GBT1118 had strong antihypoxemic therapeutic effects with improved arterial oxygen saturation to near normal level. Moreover, GBT1118 treatment significantly attenuated bleomycin‐induced lung fibrosis, collagen accumulation, body weight loss, and leukocyte infiltration. This study is the first to suggest the beneficial effects of hemoglobin modification in fibrotic lungs and offers a promising and novel therapeutic strategy for the treatment of hypoxemia associated with chronic fibrotic lung disorders in human, including IPF.
Idiopathic pulmonary fibrosis (IPF) is a chronic disease of unknown etiology that is characterized by progressive fibrotic destruction of the lung, resulting in worsening dyspnea and progressive loss of lung function (Wilson and Wynn 2009; Raghu et al. 2011). Currently, about 5 million people worldwide are affected by IPF with over 130,000 patients in the United States. The median patient survival time is approximately 4 years from the time of diagnosis (Raghu et al. 2006, 2011). Until recently, there were no approved therapies for IPF. In 2015, the antifibrotic drugs, pirfenidone and nintedanib, were approved based on demonstrating a reduction in the decline of lung function (Forced vital capacity). However, a survival advantage was not found, nor were key disease symptoms consistently clinically impacted (King et al. 2014; Richeldi et al. 2014; Harari and Caminati 2015). Therefore, there continues to be a significant need for novel and effective therapeutic drugs for IPF patients, especially to improve symptoms and quality of life (QOL).
A prominent clinical feature of IPF is progressive hypoxemia, resulting in exertional dyspnea and eventually dyspnea at rest. The recently approved drugs did not have a significant impact on oxygen saturation or dyspnea (Nishiyama et al. 2007; Parshall et al. 2012; Bodempudi et al. 2014). Dyspnea or hypoxemia induced physical activity limitation is a prominent driver of QOL impairment among IPF patients (Swigris et al. 2014). Hypoxemia caused by pulmonary fibrosis refers to oxygen deficiency in arterial blood and reduced percentage saturation of hemoglobin (Hb) with oxygen. When oxygen (O2) loading of Hb is compromised in the disease lungs, such as fibrotic lungs, an increase in Hb–O2 affinity may be of benefit by improving the loading of Hb with O2, consequently increasing arterial O2 content and O2 delivery to tissues. In support of this hypothesis, increased Hb–O2 affinity has been shown to increase survival, improve cardiovascular function, and systemic oxygenation during acute hypoxia (Eaton et al. 1974; Yalcin and Cabrales 2012). Moreover, humans or animals with high Hb–O2 affinity adapt better to acute and long‐term exposures to high‐altitude hypoxia than their relatives with normal Hb–O2 affinity (Hebbel et al. 1978; Black and Tenney 1980).
The Hb–O2 affinity can be modified with Hb allosteric effectors. GBT1118 is an analog of GBT440, a novel orally bioavailable small molecule that binds covalently and reversibly via Schiff base to the N‐terminal valine of the Hb alpha chain and allosterically modulates the Hb–O2 affinity (Oksenberg et al. 2016). It elicits a concentration‐dependent left shift in the O2–Hb dissociation curve with subsequent increase in Hb–O2 affinity and arterial O2 loading (Oksenberg et al. 2016). Therefore, we investigated whether pharmacologically increasing Hb–O2 affinity with GBT1118 could ameliorate hypoxemia associated with lung fibrosis induced by bleomycin in mice (Degryse and Lawson 2011; Moore et al. 2013). This article reports the profound antihypoxemic and potential antifibrotic effects of GBT1118 achieved via increasing Hb–O2 affinity. These data establish pharmacological modification of Hb–O2 affinity as a promising and novel therapeutic strategy for the treatment of chronic fibrotic lung disorders and pave the way for the clinical development of “first in class” molecules that treat IPF symptoms by improving hypoxemia.
Materials and Methods
The in‐life portion of the mouse study was performed at Aragen Biosciences (Morgan Hill, CA). Forty‐eight C57B/L6 male mice aged 7–8 weeks (Simonsen Laboratory, Gilroy, CA) were studied. Animals were administered 3 U/kg bleomycin sulfate USP (Teva Pharmaceuticals, North Wales, PA) or saline via oropharyngeal route (Walters and Kleeberger 2008). Body weights of all mice were recorded daily during the study. Animals were closely monitored on the days of dosing and daily until the end of the study.
Administration of GBT1118
GBT1118 was synthesized at Global Blood Therapeutics and formulated in dimethylacetamide:polyethylene glycol 400 (PEG400):40% cavitron at a 1:5:4 ratio. GBT1118 (low dose: first day 50 mg/kg followed by 40 mg/kg daily; or high dose: first day 150 mg/kg followed by 85 mg/kg daily) or vehicle control was administered via oral gavage to bleomycin‐treated mice once daily from days 8 to 15 (Walters and Kleeberger 2008).
The oral exposure of GBT1118 and Hb–O2 dissociation curve measurements were conducted at Global Blood Therapeutics (South San Francisco, CA) and determined by the methods described previously (Oksenberg et al. 2016). Samples were taken 4 h following the last dose of the chronic dosing regimen.
Arterial blood gases and O2 saturation analysis
On days 7 and 14 after bleomycin or saline administration, 50 μL of arterial blood from the tail artery were used for the measurement of arterial oxygen saturation (SaO2) using a whole blood co‐oximeter (GEM OPL; Instrumentation Laboratory, Bedford, MA). An additional 100 μL aliquot of blood was collected from the tail artery and arterial blood gases (ABG) were measured using i‐STAT Handheld Blood Analyzer (ABBOTT, Lake Bluff, IL). For each mouse, arterial pH, pCO2 (partial pressure of carbon dioxide, mmHg), and pO2 (partial pressure of O2, mmHg) were measured.
Bronchoalveolar lavage fluid analysis
Bronchoalveolar lavage fluid (BALF) was collected from the lungs of the animals by lavaging the lung with 1 mL Hank's balanced salt solution. The BALF was centrifuged and leukocytes in the cell pellet were counted using the trypan blue exclusion method. Collagen content of the BAL was determined by quantifying total soluble collagen in the BALF supernatant using the Sircol collagen dye binding assay according to the manufacturer's instructions (Biocolor Ltd., Carrick Fergus, U.K.).
The histopathological analysis was conducted at Seventh Wave Laboratories (Chesterfield, MO). The lung samples were processed and embedded with all lobes from each mouse in one paraffin block. Coronal sections through the four major lobes were stained with Masson's trichrome. For each animal, consecutive lung fields were examined in a raster pattern using a 20× objective lens and a 10× ocular lens (200×). A modified Ashcroft score (Hubner et al. 2008) was recorded for each field.
All data are presented as mean (±standard error of the mean, SEM). Groups are compared by t test and one‐way ANOVA. Statistical comparison and graphical representations were performed using Prism 6.0 (GraphPad software, San Diego, CA). Differences were considered statistically significant if P‐value was less than 0.05.
GBT1118 increases Hb affinity for O2 in vivo
Mice were randomized into four treatment groups: high‐dose GBT1118, low‐dose GBT1118, GBT1118 vehicle, or saline. Animals were administered a single oropharyngeal dose of bleomycin (BLM, 3 U/kg) or saline on day 0. The development of fibrosis before day 8 was confirmed by histopathology (Fig. 1B, C). Subsequently from days 8 to 15 the GBT1118‐treated animals were administered one of two different dosing regimens (low dose: first day loading dose 50 mg/kg followed by maintenance dose 40 mg/kg daily; or high dose: first day 150 mg/kg followed by 85 mg/kg daily) once daily (QD) from days 8 to 15 (Fig. 1A).
The pharmacokinetic profile of GBT1118 in bleomycin‐treated mice shows the low‐ and high‐dose regimens of GBT1118 achieved 18.0% and 36.7% of calculated Hb occupancy, respectively. Hb occupancy represents the proportion of Hb bound by GBT1118 and was calculated as the ratio of the concentration of GBT1118 to Hb in blood. GBT1118 was found to quickly partition into the red blood cells (RBCs) with a high blood/plasma ratio of approximately 22:1 which is equivalent to RBC/plasma ratio of 102:1 (Fig. 2A). This high RBC/plasma ratio indicated a preferential partitioning of GBT1118, into the RBCs and with the relatively low concentration in plasma off target toxicities should be minimized and the therapeutic index maximized.
The Hb–O2 dissociation curves were determined ex vivo in whole blood and correlated with the GBT1118 blood concentrations following oral dosing for 8 consecutive days in bleomycin‐treated mice. The representative Hb–O2 dissociation curves from GBT1118‐treated mice demonstrated a significant left shift in a dose‐dependent manner indicating a higher Hb–O2 binding affinity (Fig. 2B). These data indicate that oral dosing of GBT1118 increases Hb–O2 affinity in bleomycin‐treated mice.
Administrations of GBT1118 rescue bleomycin‐induced hypoxemia
Responses to hypoxia in mice treated with GBT1118 were first evaluated by measuring SaO2. SaO2 decreased over time in bleomycin‐treated mice. Both GBT1118‐treated groups showed a decrease in SaO2 on day 7 before GBT1118 treatment and subsequent return toward control values following treatment with GBT1118 for 7 consecutive days. In contrast, arterial oxygenation levels of vehicle‐treated mice further declined throughout the study (Fig. 3A). Please note the degree of hypoxemia was relatively mild in this bleomycin model and completely rescued by both doses of GBT1118 treatment. These findings demonstrate that GBT1118 treatment significantly reduces hypoxemia by increasing O2 saturation and therefore O2 content.
In addition, the ABG were analyzed on days 7 and 14. At day 7, in bleomycin‐treated mice, arterial O2 tension (PaO2) was significantly decreased, indicating an impairment of pulmonary gas exchange. In vehicle‐treated bleomycin mice, the PaO2 continued to decline until day 14. In contrast, low‐dose GBT1118 treatment prevented further decline of PaO2, indicating a beneficial effect on disease progression. In the high‐dose GBT1118 group, a trend for an increase in PaO2 was observed (Fig. 3B). No significant changes were observed on arterial carbon dioxide tension (PaCO2) and pH measurement (Fig. 3B).
Administrations of GBT1118 ameliorate bleomycin‐induced lung fibrosis
A recognized feature of bleomycin‐induced lung fibrosis in small rodents is prominent loss of body weight. In mice administered with saline, daily weight gain was observed. Animals treated with bleomycin and vehicle showed typical and persistent body weight loss after bleomycin exposure. In contrast, bleomycin challenged animals treated with either doses of GBT1118 underwent steady weight gain after the start of dosing GBT1118 on day 8, despite transient body weight loss prior to GBT1118 treatment (Fig. 4A). These data indicate that treatment with GBT1118 improves the overall health status in bleomycin‐treated animals.
In the bleomycin model, mice develop extensive pulmonary fibrosis as well as a profound leukocyte infiltration into lungs; thus, the effect of GBT1118 treatment on the alteration of pulmonary leukocyte numbers was examined. We found that treatment with GBT1118 was associated with decreased inflammation, as evidenced by a significant reduction in total leukocyte cells recovered in BALF on day 15 (Fig. 4B). This finding demonstrates that GBT1118 treatment attenuates pulmonary inflammation in this model.
The key marker of bleomycin‐induced lung fibrosis is excessive collagen deposition. As expected, when compared to saline control, bleomycin administration led to an elevation in soluble collagen content in BALF on day 15 as assessed by a Sircol collagen dye binding assay. GBT1118 treatment resulted in a significant reduction in soluble collagen protein in the lungs (Fig. 5A). The reduction in fibrosis was confirmed by quantitative measurement of lung wet weights at necropsy. The lungs of bleomycin mice administered with vehicle control were significantly heavier than lungs from GBT1118‐treated mice, suggestive of reduced fibrotic disease in treated animals (Fig. 5B). These results indicate that GBT1118 improves pulmonary fibrosis in the bleomycin murine model.
To confirm the therapeutic effects of GBT1118 treatment on the indices of pulmonary fibrosis, lung sections from day 15 mice were stained with Masson's trichrome to visualize collagen deposition. Vehicle‐treated bleomycin lungs were fibrotic and had extensive collagen deposition, thickened pulmonary interalveolar septum, and obliteration of the alveolar airspaces by collagen. In contrast, GBT1118‐treated lungs showed diminished collagen deposition in both doses; many alveoli did not exhibit septal fibrosis and resembled the parenchyma in lungs without bleomycin exposure (Fig. 5C). Ashcroft scoring to quantify morphologic fibrosis was performed, and GBT1118 treatment improved overall scores by approximately 50% (Fig. 5D). These results suggest that GBT1118 inhibits pulmonary fibrosis in this bleomycin mouse model.
Suitable animal models of IPF are lacking (Roman et al. 2013) and have been identified as a research priority for the IPF field (White et al. 2016). In our attempt to elucidate the efficacy of GBT1118 drug effects were explored in the most commonly used animal model of lung fibrosis: the bleomycin‐induced model. The results from this in vivo therapeutic study provide support for the potential use in IPF of a molecule that increases Hb–O2 affinity. GBT1118 treatment not only restored arterial O2 to normal levels, but also significantly inhibited the increase in numbers of inflammatory cell infiltrates, reduced collagen in BALF, and resulted in an approximately 50% reduction in fibrosis (histopathological changes in lung tissue). Additionally, GBT1118 administration ameliorated the loss of body weight associated with bleomycin exposure.
Exertional dyspnea and worsening hypoxia associated with hypoxemia are prominent clinical features of IPF progression as fibrosis increases and ventilation–perfusion mismatch worsens. With worsening hypoxemia patient QOL for IPF patients is significantly impacted including limitation of their daily activities. The data from this study suggest that a Hb modifier that enhances Hb–O2 affinity and improves arterial O2 uploading could potentially be used to treat hypoxemia associated with pulmonary fibrosis. Although a GBT1118‐induced left shift could theoretically decrease O2 release from Hb, our in vitro data show that GBT1118‐modified Hb remains sensitive to the Bohr effect with intact unloading of O2 under low‐pH conditions, and in vivo data from different animal models of hypoxia challenge are consistent with increased O2 extraction and consumption by tissues but not any tissue hypoxia (Yalcin and Cabrales 2012; Cabrales et al. 2015; Oksenberg et al. 2016).
The health benefits of modifying Hb could be substantial: improvement of hypoxemia can prevent dyspnea and help patients preserve an active lifestyle and a better QOL. Moreover, it could potentially impact the associated comorbidities of IPF including pulmonary hypertension and sleep‐disordered breathing. Reduction in nocturnal desaturations and the detrimental effects of systemic hypoxemia associated with obstructive sleep apnea, which has a prevalence as high as 88% in patients with IPF (Lancaster et al. 2009; Pihtili et al. 2013), may impact the course of IPF and associated complications (Kolilekas et al. 2013; Mermigkis et al. 2015).
Interestingly, the data suggest that a Hb modifier that improves hypoxemia in this bleomycin model could potentially retard the progression of pulmonary fibrosis. A dose response of GBT1118 was not seen here, which may be due to the fact that the degree of hypoxemia was relatively mild and completely rescued by both doses (Fig. 3A). It will be necessary to inspect whether GBT1118 has direct effects on oxidant activity, inflammation, and fibrosis in the future. Despite these, the overall beneficial effects of GBT1118 were clear. The role of hypoxia driving the progressive fibrotic nature of the disease has not been fully explored previously. In aggregate, our own and previously published data might indicate a potential role for hypoxia signaling in the pathogenesis of pulmonary fibrosis (Jain and Sznajder 2005; Tzouvelekis et al. 2007; Rabbani et al. 2010; Kottmann et al. 2012; Bodempudi et al. 2014). It is possible that a pathological loop exists in the fibrotic lung, in which hypoxia promotes fibroblasts proliferation and inflammatory damages, which in turn worsen hypoxia. It would be very interesting to further study how increased O2 saturation could benefit pulmonary injury, inflammation, or fibrosis.
In summary, this study supports further clinical evaluation of allosteric Hb modifiers as a novel therapeutic strategy for treating hypoxemia associated with pulmonary fibrosis and potentially retarding the progression of pulmonary fibrosis. GBT440, an analog of GBT1118 that increases Hb–O2 affinity and arterial O2 loading as well, is currently in clinical trials for the treatment of sickle cell disease and has demonstrated excellent safety and biological effects in both healthy subjects and subjects with sickle cell disease (NCT02285088, http://clinicaltrials.gov/) (Oksenberg et al. 2016).
Conflict of Interest
All authors of this manuscript are paid employees and stockholders of Global Blood Therapeutics.
No funding information provided.
- Manuscript Received: August 9, 2016.
- Manuscript Revised: August 16, 2016.
- Manuscript Accepted: August 17, 2016.
- © 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.